Bridgeway Capital Management’s OnKure Therapeutics OKUR Stock Holding History

Bridgeway Capital Management’s Portfolio OKUR Stock Details OKUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$229K	Buy	50,293 +34,000	+209%	+$146K	﹤0.01%	1028
2026 Q1	$67.5K	Sell	16,293 -3,207	-16%	-$9.9K	﹤0.01%	1168
2025 Q4	$56.5K	Hold	19,500	–	–	﹤0.01%	1176
2025 Q3	$53.6K	Sell	19,500 -5,500	-22%	-$13.6K	﹤0.01%	1162
2025 Q2	$59.8K	Hold	25,000	–	–	﹤0.01%	1125
2025 Q1	$108K	Buy	+25,000	New	+$141K	﹤0.01%	1026
2024 Q1	–	Sell	-9,138	Closed	-$146K	–	1384
2023 Q4	$146K	Hold	9,138	–	–	﹤0.01%	1189
2023 Q3	$696K	Buy	9,138 +3,388	+59%	+$230K	0.02%	803
2023 Q2	$377K	Buy	5,750 +3,250	+130%	+$262K	0.01%	985
2023 Q1	$150K	Sell	2,500 -4,500	-64%	-$163K	﹤0.01%	1161
2022 Q4	$163K	Buy	7,000 +2,500	+56%	+$66.3K	﹤0.01%	1136
2022 Q3	$151K	Sell	4,500 -2,500	-36%	-$82.1K	﹤0.01%	1194
2022 Q2	$186K	Sell	7,000 -3,000	-30%	-$69.8K	﹤0.01%	1106
2022 Q1	$294K	Hold	10,000	–	–	0.01%	1086
2021 Q4	$855K	Hold	10,000	–	–	0.02%	822
2021 Q3	$745K	Buy	+10,000	New	+$849K	0.01%	915

Other funds holding OKUR

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bridgeway Capital Management's OKUR Position: Q2 2026 in Review

Bridgeway Capital Management increased its OnKure Therapeutics (OKUR) stake by 209% in Q2 2026, buying an estimated $146K and bringing the position to 50,293 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #1028.

Bridgeway Capital Management first reported a position in OKUR in Q3 2021 and has held it in 16 quarters since. The position peaked at $855K in Q4 2021. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

Bridgeway Capital Management held 50,293 shares of OnKure Therapeutics worth $229K as of Q2 2026.
Bridgeway Capital Management bought 34,000 OnKure Therapeutics shares in Q2 2026, an estimated $146K.
OnKure Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #1028 holding.
Bridgeway Capital Management first reported a position in OnKure Therapeutics in Q3 2021 and has held it in 16 quarters since.
Bridgeway Capital Management's OnKure Therapeutics position peaked at $855K in Q4 2021.
75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.